137 related articles for article (PubMed ID: 38748758)
1. Novel approach to HER2 quantification using phosphor-integrated dots in human breast invasive cancer microarray.
Saito N; Matsuo T; Tsuda H; Yokota H; Okada H
PLoS One; 2024; 19(5):e0303614. PubMed ID: 38748758
[TBL] [Abstract][Full Text] [Related]
2. Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry.
Helin HO; Tuominen VJ; Ylinen O; Helin HJ; Isola J
Virchows Arch; 2016 Feb; 468(2):191-8. PubMed ID: 26493985
[TBL] [Abstract][Full Text] [Related]
3. A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study.
Hicks DG; Buscaglia B; Goda H; McMahon L; Natori T; Turner B; Soukiazian A; Okada H; Nakano Y
BMC Cancer; 2018 Dec; 18(1):1266. PubMed ID: 30563489
[TBL] [Abstract][Full Text] [Related]
4. Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.
Scheel AH; Penault-Llorca F; Hanna W; Baretton G; Middel P; Burchhardt J; Hofmann M; Jasani B; Rüschoff J
Diagn Pathol; 2018 Mar; 13(1):19. PubMed ID: 29530054
[TBL] [Abstract][Full Text] [Related]
5. AutoIHC-Analyzer: computer-assisted microscopy for automated membrane extraction/scoring in HER2 molecular markers.
Tewary S; Arun I; Ahmed R; Chatterjee S; Mukhopadhyay S
J Microsc; 2021 Jan; 281(1):87-96. PubMed ID: 32803890
[TBL] [Abstract][Full Text] [Related]
6. Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer.
Yamada M; Kubo M; Yamamoto H; Yamashita N; Kai M; Zaguirre K; Kaneshiro K; Shimazaki A; Hayashi S; Kawaji H; Mori M; Oda Y; Nakamura M
Anticancer Res; 2021 Aug; 41(8):4143-4149. PubMed ID: 34281885
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
Sun H; Kang EY; Chen H; Sweeney KJ; Suchko M; Wu Y; Wen J; Krishnamurthy S; Albarracin CT; Ding QQ; Foo WC; Sahin AA
Breast Cancer Res Treat; 2024 Jun; 205(2):403-411. PubMed ID: 38441847
[TBL] [Abstract][Full Text] [Related]
8. Quantitative diagnostic imaging of cancer tissues by using phosphor-integrated dots with ultra-high brightness.
Gonda K; Watanabe M; Tada H; Miyashita M; Takahashi-Aoyama Y; Kamei T; Ishida T; Usami S; Hirakawa H; Kakugawa Y; Hamanaka Y; Yoshida R; Furuta A; Okada H; Goda H; Negishi H; Takanashi K; Takahashi M; Ozaki Y; Yoshihara Y; Nakano Y; Ohuchi N
Sci Rep; 2017 Aug; 7(1):7509. PubMed ID: 28790306
[TBL] [Abstract][Full Text] [Related]
9. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
[TBL] [Abstract][Full Text] [Related]
10. Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.
Fitzgibbons PL; Murphy DA; Dorfman DM; Roche PC; Tubbs RR;
Arch Pathol Lab Med; 2006 Oct; 130(10):1440-5. PubMed ID: 17090184
[TBL] [Abstract][Full Text] [Related]
11. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays.
Laurinaviciene A; Dasevicius D; Ostapenko V; Jarmalaite S; Lazutka J; Laurinavicius A
Diagn Pathol; 2011 Sep; 6():87. PubMed ID: 21943197
[TBL] [Abstract][Full Text] [Related]
12. Quantitative diagnosis of HER2 protein expressing breast cancer by single-particle quantum dot imaging.
Miyashita M; Gonda K; Tada H; Watanabe M; Kitamura N; Kamei T; Sasano H; Ishida T; Ohuchi N
Cancer Med; 2016 Oct; 5(10):2813-2824. PubMed ID: 27666577
[TBL] [Abstract][Full Text] [Related]
13. Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.
Ohkuma R; Miura S; Muto S; Toyomasu Y; Fujimoto Y; Ieguchi K; Onishi N; Shimizu T; Watanabe M; Takayanagi D; Goshima T; Horiike A; Hamada K; Ariizumi H; Shimokawa M; Hirasawa Y; Ishiguro T; Suzuki R; Iriguchi N; Tsurui T; Mura E; Takenoshita S; Numajiri K; Okabe N; Yoshimura K; Tsuji M; Kiuchi Y; Yajima T; Ishida H; Suzuki H; Yamochi T; Kobayashi S; Tsunoda T; Wada S
Front Immunol; 2023; 14():1260492. PubMed ID: 37790929
[TBL] [Abstract][Full Text] [Related]
14. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
15. Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification.
Varga Z; Tubbs RR; Moch H
PLoS One; 2014; 9(8):e105961. PubMed ID: 25153153
[TBL] [Abstract][Full Text] [Related]
16. High agreement between whole slide imaging and optical microscopy for assessment of HER2 expression in breast cancer: whole slide imaging for the assessment of HER2 expression.
Nunes C; Rocha R; Buzelin M; Balabram D; Foureaux F; Porto S; Gobbi H
Pathol Res Pract; 2014 Nov; 210(11):713-8. PubMed ID: 25091257
[TBL] [Abstract][Full Text] [Related]
17. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
18. Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry.
Taylor VJ; Barnes PJ; Godwin SC; Bethune GC
Virchows Arch; 2021 Jul; 479(1):23-31. PubMed ID: 33527151
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelines.
O'Grady A; Allen D; Happerfield L; Johnson N; Provenzano E; Pinder SE; Tee L; Gu M; Kay EW
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):489-93. PubMed ID: 20661132
[TBL] [Abstract][Full Text] [Related]
20. Automated segmentation of cell membranes to evaluate HER2 status in whole slide images using a modified deep learning network.
Khameneh FD; Razavi S; Kamasak M
Comput Biol Med; 2019 Jul; 110():164-174. PubMed ID: 31163391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
